C. Rosazza

P061 Monitoring the effectiveness of elexacaftor/tezacaftor/ivacaftor therapy in children and adolescents with cystic fibrosis and normal spirometry

G. Alicandro, V. Terlizzi, Maria Chiara Russo, Laura Elisabetta Claut et autres

it (code pays fourni par la source)

P159 Long COVID in people with cystic fibrosis: a prospective observational study within the Italian Cystic Fibrosis Society

C. Colombo, P. Medino, Giovanni Taccetti, F. Lucca et autres

it (code pays fourni par la source)

718 Lung clearance index decreases in patients who do not achieve clinically meaningful improvement in ppFEV1 after elexacaftor-tezacaftor-ivacaftor therapy

E. Nazzari, G. Alicandro, L. Zazzeron, C. Rosazza et autres

us (code pays fourni par la source)

P153 An Italian centre experience with elexacaftor/tezacaftor/ivacaftor therapy in 6 to 11 year olds with cystic fibrosis

C. Rosazza, Gianfranco Alicandro, L. Zazzeron, Maria Chiara Russo et autres

it (code pays fourni par la source)

534 COVID-19 in people with cystic fibrosis and the general population: Severity and virus-host cell interactions

C. Colombo, G. Alicandro, A. Bandera, V. Bouché et autres

it (code pays fourni par la source)

P054 Severity of COVID-19 infection in cystic fibrosis patients compared to the general population

C. Rosazza, P. Medino, A. Bandera, M.S. Boraso et autres